Coronado announced the initiation of an investigator-sponsored pilot study to evaluate CNDO-201 (TSO) for the treatment of moderate-to-severe psoriasis. This is first new TSO study since Harlan Weisman joined the Company as CEO in early January. As a reminder, Weisman led the development of Remicade, JNJ’s best-selling product and approved for several of the same indications[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.